Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025)
Fortrea Holdings' (FTRE) quarterly Cash from Financing Activities came in at -$75.7 million in Q4 2025, down 6781.82% YoY from $1.1 million in Q4 2024, and down 51.4% on a QoQ basis from -$50.0 million in Q3 2025.
Analysis
Fortrea Holdings (FTRE) Cash from Financing Activities (2022 - 2025) Analysis & Trends
Fortrea Holdings (FTRE) has 4 years of Cash from Financing Activities data on file, last reported at -$75.7 million in Q4 2025.
- Quarterly Cash from Financing Activities fell 6781.82% year-over-year to -$75.7 million in Q4 2025, while the trailing twelve-month figure through Jun 2026 was -$125.7 million (down 466.47% YoY) and the FY2025 annual result came in at -$76.3 million, up 84.67% from the prior year.
- Cash from Financing Activities slipped to -$75.7 million in Q4 2025, from -$50.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $88.4 million in Q1 2025 to a low of -$504.0 million in Q2 2024.
- A 4-year average of -$54.8 million and a median of -$10.8 million in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 315.02% in 2025, down 6781.82% in 2025.
- Tracing FTRE's Cash from Financing Activities over 4 years: stood at -$5.9 million in 2022, then tumbled by 30.51% to -$7.7 million in 2023, then jumped by 85.71% to -$1.1 million in 2024, then tumbled by 6781.82% to -$75.7 million in 2025.
- The last three Cash from Financing Activities figures came in at -$75.7 million (Q4 2025), -$50.0 million (Q3 2025), and -$39.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Fortrea Holdings | 1.72 Bn | 1.55 Bn | 139.20 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -75.70 Mn |
| Sep 30, 2025 | -50.00 Mn |
| Jun 30, 2025 | -39.00 Mn |
| Mar 31, 2025 | 88.40 Mn |
| Dec 31, 2024 | -1.10 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Jun 30, 2024 | -504.00 Mn |
| Mar 31, 2024 | 21.30 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Jun 30, 2023 | -149.90 Mn |
| Mar 31, 2023 | 24.50 Mn |
| Dec 31, 2022 | -5.90 Mn |
| Sep 30, 2022 | -46.50 Mn |